24/7 Wall St. on MSN18h
AbbVie Just Paid Investors: Here's How Much They ReceivedAbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...
We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going ...
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...
Xilio Therapeutics Inc. is banking $52 million up front from Abbvie Inc., including a $10 million equity investment, plus about $2.1 billion in contingent payments for option-related fees and ...
In a remarkable display of market confidence, AbbVie Inc (NYSE:ABBV)'s stock has soared to an all-time high, reaching a price level of $198.36. This significant milestone... On Tuesday, Deutsche ...
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including ...
Investing.com -- Shares of Xilio Therapeutics Inc surged 175% on Wednesday in pre-market trading following the announcement ...
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
Shares in biotech group Xilio Therapeutics ($XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback